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The pegylated interferon regimen has long been the lone effective management of chronic hep-
atitis C with modest response. The ﬁrst appearance of protease inhibitors included boceprevir
and telaprevir. However, their efﬁcacy was limited to genotype 1. Recently, direct antiviral
agents opened the gate for a real effective management of HCV, certainly after FDA approval
of some compounds that further paved the way for the appearance of enormous potent direct
antiviral agents that may achieve successful eradication of HCV.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.
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Introduction
The ﬁrst generation of protease inhibitors included boceprevir






lasses of direct antiviral agents (DAA).ribavirin, they improved the overall rates of sustained virolog-
ical response (SVR). This included treatment naı¨ve as well as
experienced patients [1–10]. However, this efﬁcacy was limited
to patients with hepatitis C virus genotype 1 infection, was
associated with numerous side effects and needed a frequent
dosing schedule [11].
With recent advances, many direct antiviral agents (DAA)
developed and led to a more promising future for HCV
infected patients. Excellent advantages were related to their
high potency, pangenotypic coverage and intermediate to high
barrier to resistance [12]. They paved the way to the possible
application of oral interferon-free regimens. In addition, these
regimens can be taken once daily and may result in global
HCV eradication in near future [13].
Three major classes of DAA dominated the scenario at dif-
ferent stages of development and clinical practice: NS3/4A
protease inhibitors, NS5B polymerase inhibitors and NS5A
direct inhibitors (Figs. 1 and 2). NS5B polymerase inhibitors
are further categorized into two distinct groups: the nucleoside
polymerase inhibitors (NIs) and the nonnucleoside polymerase
inhibitors (NNIs). NIs interact with the catalytic site for NS5B
affecting viral RNA synthesis. They are characterized by their
high barrier of resistance [14,15]. NNIs bind to different allo-
steric sites on the NS5B protein and prevent effective viral
RNA synthesis. Their efﬁcacies differ according to HCV geno-
types and subtypes. They have a lower barrier of resistance
[16].
NS5A inhibitors showed promising results among the dif-
ferent DAA drug studies due to their multigenotypic efﬁcacy,
high potency but low to intermediate barrier to resistance.
Such DAA are used in combination with interferon and riba-
virin to prevent virologic breakthrough and subsequent resis-
tance. Similarly, they synergize with other DAA to suppress
the development of resistant virus strains [17–19].The most important direct antiviral agents
Sofosbuvir
Sofosbuvir is a prodrug of 20-deoxy-20-ﬂuoro-20-C-methyluri-
dine monophosphate. It is a speciﬁc nucleotide analog inhibi-
tor of the HCV NS5B polymerase acting as a false substrate
for the RdRp and ending at chain termination after incorpora-
tion into the newly produced RNA chain [20]. It is character-
ized by its broad antiviral activity against all HCV genotypes
[21]. Sofosbuvir is a 400 mg once-daily capsule, which can be
taken with or without food. It is mainly excreted by the kid-
neys at a rate of 76% with a median half life ranging from
0.48 to 0.75 h [22]. Metabolism of sofosbuvir and the other
related drugs of the same family have no relation with the
CYP3A4 pathway. So, they have a low potential for drug-drug
interaction [23,24].
S282T mutation is determined as the common mutation
occurring in replicon studies with sofosbuvir [25]. This muta-
tion has reduced replicative capacity as compared to the wild
type containing replicons [26,27]. In a study using sofosbuvir
containing regimen, patients who failed to achieve SVR
showed undetectable S282T mutation, either at baseline or
later [28].
Sofosbuvir has been studied in different combinations
(Table 1). The value of adding sofosbuvir to the combination
Fig. 2 Differences between the different DAA classes.
DAAs for HCV therapy 303of Peg-IFNa in genotype 1 patients was ﬁrst addressed in two
phase II trials (PROTON and ATOMIC) [29,30]. The ﬁrst
study (PROTON) tested the addition of 400 mg sofosbuvir
versus placebo to the combined IFN/RBV regimen for
12 weeks followed by an additional 12 or 36 weeks of Peg-
IFNa and RBV. The 91% SVR12 in sofosbuvir arm compared
to the 40% ﬁgure in placebo group was striking. The other trial
(ATOMIC) evaluated the role of maintenance therapy after
the initial 12 week response. SVR rated between 90% and
94%. This occurred regardless of the use of maintenance ther-
apy. This based the 12 week triple therapy regimen for phase
III NEUTRINO study [31]. In this study, 327 naı¨ve patients
with different genotypes (1, 4, 5 and 6) were treated for
12 weeks in an open-label single-arm design with sofosbuvir
400 mg and RBV 1000–1200 mg daily in addition to weekly
Peg-IFNa 180 lg. The historic SVR12 of 60% was used for
comparison. According to the treated HCV genotype, the
results were 89% in HCV type 1, 96% in HCV type 4 and
100% in seven patients with HCV types 5 and 6. The overall
response was 90%.
Sofosbuvir was the ﬁrst drug to test the concept of ‘‘inter-
feron free’’ regimens. Many phase II studies were conducted
to evaluate the efﬁcacy of various sofosbuvir combination reg-
imens [32,33]. The sofosbuvir based interferon free regimens
were either: sofosbuvir plus RBV, sofosbuvir plus anotherTable 1 Different sofosbuvir studies.
Name of study Design Genotype SVR (%)
PROTON Sof, IFN/RBV 1 91
ATOMIC Sof, IFN/RBV 1,4,6 90–94
NEUTRINO Sof, IFN/RBV 1,4,5,6 89–100
ELECTRON Sof, RBV 1 88
Sof, RBV, Ledipasvir 100
Sof, RBV, GS-9669 92
QUANTUM Sof, RBV 1 56
FISSION Sof, RBV 2,3 67
FUSION Sof, RBV 2,3 56–73
POSITRON Sof, RBV 2,3 61–93
LONESTAR Sof, RBV, Ledipasvir 1 95–100DAA or sofosbuvir plus another DAA and RBV for different
treatment durations (8–24 weeks). Studies that tested for sof-
osbuvir in genotype 1 included QUANTUM and
ELECTRON studies. Fifty naı¨ve patients were treated with
sofosbuvir and ribavirin for 12 weeks. SVR12 rates were
56% and 88% respectively [34,35]. No obvious improvement
in SVR was noted when treatment duration extended up to
24 weeks in a subgroup of patients in the QUANTUM and
NIH SPARE studies [34–36]. Results of FUSION trial that
used the same duration (24 weeks) in genotypes 2 and 3 led
to signiﬁcant improvement of SVR from 56% to 73% [37].
Impressive results are shown in studies that used sofosbuvir
combined with other DAA. Most of studies proved that riba-
virin use will be of no value [32,36]. Many regimens with dif-
ferent DAA were used with either a non-nucleoside
polymerase inhibitor or a NS5A inhibitor with no signiﬁcant
differences in response. The addition of one of the nucleotide
analogs (GS-0938) to sofosbuvir for 12 weeks resulted in
SVR12 in 88% while SVR4 after 12 weeks of a combination
of sofosbuvir and daclatasvir (NS5A inhibitor) or ledipasvir
(GS-5885) was as high as 98% and 100% [38,39]. Shortening
of treatment duration in LONESTAR trial that used sofosbu-
vir and ledipasvir for 8 weeks resulted in 95% SVR8 [38].
Treatment experienced patients were the target group in
many sofosbuvir trials. In ELECTRON study, 12-week sof-
osbuvir plus RBV were tested in 10 genotype 1 patients with
previous treatment failure and led to high relapse rates [32].
It differed when another DAA was used with sofosbuvir for
12 weeks in this difﬁcult to treat group of patients. The SVR
results in these DAA combination studies ranged 90–100%.
Many DAA were used in combination with sofosbuvir as
NS5A inhibitor ledipasvir or daclatasvir, the protease inhibitor
simeprevir or the non-nucleoside polymerase inhibitor GS-
9669 [33,38,39].
ELECTRON study assessed the use of sofosbuvir plus riba-
virin in genotypes 2 and 3 for 12 weeks with/without Peg-IFNa
[32]. The nonsigniﬁcant value of added interferon paved the
way for further interferon free trials.
For genotypes 2 and 3, interferon free regimens were
assessed in phase III trials (FISSION, FUSION and
POSITRON) where combined sofosbuvir and RBV were given
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the FISSION study in 256 naı¨ve patients with SVR reached
about 67% [31]. The 16 week instead of 12 week duration
was tested in the FUSION study that recruited previous treat-
ment failure patients. The overall SVR rates were 50% in the
12 week and 73% in the 16 week arms [40]. The POSITRON
trial studied the effectiveness of 12 weeks of combination of
sofosbuvir and RBV in patients with HCV type 2 or 3 who
are ineligible for Peg-IFNa-based therapies due to contraindi-
cations, unacceptable previous adverse events or unwillingness
to receive Peg-IFNa therapy. The overall SVR rates were 61–
93% according to RBV dose [37].Daclatasvir
Daclatasvir, produced by Bristol-Myers Squibb, is the ﬁrst-in-
class NS5A inhibitor that demonstrated a satisfactory multi-
phase rapid HCV RNA decline without signiﬁcant adverse
events. It is highly effective against genotypes 1–4 [41,42].
Several clinical trials assessed the efﬁcacy of daclatasvir with
different compounds.
Using daclatasvir with interferon and ribavirin, Suzuki
et al. managed HCV patients who were treatment naı¨ve, prior
null or partial responders. Two Different concentrations of
daclatasvir were used (10 and 60 mg) versus a placebo group.
SVR24 reached 66.7–90% in naı¨ve group versus 62.5% in pla-
cebo group and much less satisfactory results in prior null
responders (22–33.3%) [43]. Better results were achieved by
Izumi and colleagues. Naı¨ve group had SVR24 89–100% while
null responders group 50–78% [44].
Other trials looked for daclatasvir combinations with
asunaprevir. A phase III trial was accomplished in 24
Japanese centers to manage genotype 1b HCV patients who
were either interferon ineligible/intolerant or nonresponders.
SVR24 was 87.4% in interferon ineligible versus 80.5% in null
responder patients. Cirrhotic patients achieved 90.9% SVR24.
Side effects included nasopharyngitis, elevated liver enzymes,
headache, diarrhea and pyrexia [45]. Another study found
90.5% SVR in null responders while 63.6% in ineligible/intol-
erant patients [46]. Moreover, further results were published by
Lok et al. who used different combinations of daclatasvir with
asunaprevir (Dual), ribavirin (Triple) or interferon and ribavi-
rin (Quad) in genotype 1 null responder patients. Dual twice
daily asunaprevir and the quad therapy were effective (SVR
78% and 95% respectively). Neither dual (once daily asuna-
previr) nor triple therapy was sufﬁciently effective for such
patients [47]. Ongoing studies added BMS791325 to daclatas-
vir and asunaprevir. SVR results were recorded as 94–100%
according to treatment period (12 or 24 weeks) [48].
Excellent results were further published by Sulkowski et al.
[49]. Daclatasvir was combined with sofosbuvir for treatment
naı¨ve and treatment experienced patients infected with HCV
genotypes 1, 2 and 3. The best results were achieved with geno-
type 1 patients (98% SVR12 for both naı¨ve and prior null
responder patients). As for genotypes 2 and 3, SVR was
achieved in 92% and 89% of patients respectively. Response
rates were similar whether patients were taking ribavirin or
not. In another phase II study, SVR12 was recorded in all
genotype 1 naı¨ve and treatment experienced patients (100%)
while patients with genotype 2 or 3 succeeded to have 91%
SVR [50].Simeprevir
Simeprevir is a new direct acting antiviral drug and a second
generation NS3/4A serine protease inhibitor. It was introduced
by Janssen and Medivir for the oral treatment of patients with
genotype 1 and/or genotype 4 chronic HCV infections [51]. In
vitro, it is active against all six genotypes with lesser efﬁcacy
against genotype 3a [52,53]. Simeprevir proved to have several
advantages such as its high efﬁcacy, short treatment duration
(12–24 weeks), better safety proﬁle than ﬁrst generation drugs
and the decreased pill burden being taken once daily [54].
The PILLAR study is a phase IIb trial that was performed
to test the efﬁcacy of combined simeprevir, interferon and riba-
virin in HCV G1 infected patients who were naı¨ve and
noncirrhotic. They were compared to another group taking
interferon and ribavirin alone. SVR rates in the combined
group reached 74.7–86.1% compared to 64.9% in the second
group. Patients who met the RGT criteria had the best SVR
rates (91%). Reversible hyperbilirubinemia was recorded as a
side effect of simeprevir. Discontinuation rates were 8–16%
in the simeprevir group versus 15% in the control group [55].
The ASPIRE trial is another phase II trial that was
designed for treatment experienced HCV G1 patients. Triple
therapy (simeprevir, interferon and ribavirin) led to 85%
SVR as compared to 37% only in control group (interferon
and ribavirin). More detailed, partial responders had a SVR
75% versus 9% while prior nonresponders recorded 51% ver-
sus 19% SVR [56].
A phase III trial for treatment experienced HCV genotype 1
patients, named PROMISE study, was performed with ran-
domization of patients to simeprevir, interferon and ribavirin
versus placebo, interferon and ribavirin. Results were 79%
SVR12 versus 39% in placebo group. QUEST-1 and
QUEST-2 studies also randomized to same regimen. Higher
SVR12 rates were recorded in simeprevir group (80–81%)
compared to the placebo group (50%) [57–60].
In parallel, important randomized clinical trials were per-
formed in Japan. In the DRAGON study, 92 naı¨ve patients
infected with genotype 1 HCV were enrolled for simeprevir
(12–24 weeks) with pegylated interferon and ribavirin (24–
48 weeks) versus lone pegylated interferon and ribavirin for
48 weeks. Statistically signiﬁcant difference was observed
between simeprevir group (SVR 77–92% with relapse rate
8–17%) and the other group (SVR 46% with relapse rate
36%) [61]. CONCERTO-1 study for treatment naı¨ve G1
HCV patients found SVR 88.6% versus 61.7%.
CONCERTO-2 (for nonresponders) and CONCERTO-3
(for relapsers) concluded SVR12 rates as 35.8–52.8% for
prior nonresponders and 95.9% for prior relapsers [62,63].
Most recently, CONCERTO-4 study for both treatment
naı¨ve and experienced patients with chronic HCV genotype
1 infection was published. The highest SVR12 was achieved
by the treatment naı¨ve patients (91.7%) and prior nonrelaps-
ers (100%) while the prior nonresponders scored an SVR rate
38.5% only [64].
Ledipasvir
Ledipasvir is another NS5A inhibitor that showed promising
results in different trials that evaluated its combination to sof-
osbuvir. It provided high potency against HCV genotypes 1a,
DAAs for HCV therapy 3051b, 4a and 6a while it was less efﬁcacious against genotypes 2a
and 3a [65]. It cannot be used alone due to quick development
of resistance [66].
The LONESTAR clinical trial evaluated the use of sofosbu-
vir and ledipasvir with and without ribavirin for HCV G1
patients, either treatment naı¨ve or experienced. SVR was really
successful (98%) [67]. ELECTRON trial is a similar trial that
announced 100% SVR12 for both treatment naı¨ve and prior
nonresponder G1 patients [68]. These results are further
proved in another large clinical trial using ﬁxed doses for
untreated G1 patients. Ledipasvir combined with sofosbuvir
led to 99% SVR of total 865 patients (16% had liver cirrhosis)
[69]. Concerning the previously treated patients (n= 440),
SVR ranged 94–99% according to duration of therapy (12–
24 weeks) and whether taken with or without ribavirin [70].
Reducing the duration of therapy to 8 weeks led to 93–94%
SVR compared to 95% if the regimen was taken for 12 weeks
[71].Abt-450/ritonavir, ombitasvir and dasabuvir
ABT-450, new product of Abbvie Company (North Chicago,
USA), is a potent inhibitor of NS3/4A protease. It has been
studied with several drugs aiming to provide a possible inter-
feron free/ribavirin free ‘‘all oral’’ drug regimen in a shorter
duration of therapy [72]. Ombitasvir (ABT-267) is aFig. 3 The different direcpangenotypic inhibitor of NS5A with excellent potency, meta-
bolic stability and pharmacokinetics [73].
Different studies provided optimistic results for a future of
HCV eradication. The AVIATOR study used the combination
of ABT-450/r, ombitasvir (ABT-267), dasabuvir (ABT-333)
plus ribavirin for 8, 12 or 24 weeks in noncirrhotic G1 HCV
patients (either naı¨ve or previous treatment failure).
Treatment naı¨ve patients had a successful SVR (97.5%) as well
as treatment experienced patients (93.3%) [74].
In another clinical trial performed by Zeuzem et al., they
managed HCV G1 infected patients with ABT-450/r-ombitas-
vir and dasabuvir with ribavirin. 286 of 297 patients (96.3%)
achieved SVR12. Enrolled patients were treatment relapsers,
partial responders or null responders [75]. Feld et al. used
the same drug regimen for treatment naı¨ve patients and scored
96.2% SVR [76]. Moreover, Poordad and colleagues focused
their clinical trial on cirrhotic patients, used the same regimen
and ﬁnally concluded a successful SVR12 rate in such difﬁcult
to treat patients (91.8%) [77].
In a trial to exclude ribavirin, Ferenci et al. used the same
drug regimen excluding ribavirin and found that the rates of
virologic failure were higher in the ribavirin free group
(7.8% versus 2%) [78]. Finally, Andreone et al. concluded a
97–100% SVR with or without ribavirin in treatment experi-
enced patients with HCV G1 infection with well tolerability
as evidenced by the low rates of discontinuation and the mild
adverse events [79].t antiviral agent drugs.
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Faldaprevir is a new NS3/4A protease inhibitor that has an
acceptable tolerability and safety at all dose levels. Several
studies used it with different drug combinations. SILEN-C1
(for naı¨ve G1 HCV patients) and SILEN-C2 (for prior nonre-
sponders) were enrolled on 429 and 290 patients respectively.
Faldaprevir was used in combination with pegylated interferon
and ribavirin. SVR rates in naı¨ve, prior partial responders and
null responders were 72–84%, 32–50% and 21–35% respec-
tively. SILEN-C3 is a phase II trial for 160 naı¨ve G1 infected
patients. Faldaprevir was taken for 12–24 weeks with 24–
48 weeks of pegylated interferon and ribavirin. SVR rates were
67% (if 12 weeks) and 74% (if 24 weeks) [80–82].
Zeuzem et al. used a different drug combination. In a phase
Ib trial (SOUND-C1), faldaprevir was taken with deleobuvir
and ribavirin. Studied patients were treatment naı¨ve G1
infected persons. Two out of 32 managed patients suffered
from virological breakthrough that was successfully treated
with interferon containing therapy. SVR24 was 73% (deleobu-
vir 400 mg) and 94% (deleobuvir 600 mg) [83]. In another
phase IIb trial by Zeuzem et al., SVR12 was 52–69% according
to the drug regimen using 120 mg once daily faldaprevir with
deleobuvir 600 mg (2–3 times daily) and ribavirin (16, 28 or
40 weeks) [84].
MK-5172, MK-8742 and vaniprevir
MK-5172 is an NS3/4A protease inhibitor with a high potency
and barrier to resistance. It is taken once daily. MK-5172 is
active against multiple genotypes associated with resistance
to ﬁrst generation protease inhibitors [85,86]. It has been tested
in combination with pegylated interferon and ribavirin to man-
age patients infected with genotype 1 HCV. Achieved SVR24
ranged between 86% and 93% according to the used dose
(100, 200, 400 or 800 mg). The combination was generally well
tolerated [87]. Vaniprevir (MK-7009) is another NS3/4A pro-
tease inhibitor that reached phase III clinical trials.
Vaniprevir monotherapy showed potent antiviral activity in
genotype 1 HCV patients. It is generally well tolerated without
serious adverse events [88]. Despite the efﬁcacy of both MK-
5172 and vaniprevir, emergence of resistance reduced their
effectiveness against viral replication [89]. MK-8742 is an
NS5A inhibitor, currently in phase IIb clinical trials as an all
oral, interferon free regimen for management of HCV [90].
Being combined with MK-5172, they led to a breakthrough
therapy for HCV therapy. This study named C-WORTHY
study treated genotype 1 (1a and 1b) and declared 89–100%
SVR12 for patients using this combination with or without
ribavirin [91]. Still more progression is ongoing to provide fur-
ther MK compounds with retained high potency and pangeno-
typic activity [92].
Other compounds
Apart from the previously discussed major compounds, there
are numerous drugs and molecules at various stages of produc-
tion and different phases of trials (Fig. 3). Phase II clinical tri-
als include NS3/4A inhibitors such as danoprevir [93–95] and
NS5A inhibitors such as ACH-3102 [96], samatasvir [97],
PPI-668 [98], GSK 2336805 [99] and GS-5816 [100,101].Similarly, phase I clinical trials include NS3/4A inhibitors such
as ACH-806 [102] and NS5A inhibitors such as ACH-2928
[103] and PPI-461 [104].Conclusions
The last few years witnessed the development and appearance
of many drugs that led to potent changes in the management
of HCV. Still the future will evidence the development of much
more compounds that will provide 100% efﬁcacy within very
short periods of therapy and the dream of HCV eradication
seems to be possible in the near future.
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